Inside Putin's Russia; Is China peaking?; Knowledge in the digital age
Fareed Zakaria GPS
00:00
The Future of Obesity
Some magletide is the active ingredient in two medications flying off pharmacist shelves in the US right now. The first ozempic came on to the scene in 2017 as a diabetes treatment But the patients in clinical trials reported losing significant weight and rather than include the reaction as a side effect It's maker Novo Nordisk turned it into a lucrative selling point And you may lose weight By 2021 the Danish drug maker started selling wagovii a weight loss specific dose of some agletide aimed at treating obese and overweight adults Early results seem remarkable Company sponsored studies have indicated that those onwagovii can expect to lose around 15% of their body weight after nearly a year and a
Transcript
Play full episode
